Cimzia (certolizumab pegol) works by blocking a protein called TNF-alpha, one of the key drivers of inflammation in autoimmune diseases like rheumatoid arthritis, Crohn’s disease, and psoriasis. What makes it unusual among TNF blockers is its structure: it’s not a complete antibody. Instead, it’s a fragment of one, attached to a polymer that extends its life in the body and gives it properties no other drug in its class shares.
What TNF-Alpha Does and Why Blocking It Helps
TNF-alpha is a signaling protein your immune system releases to trigger inflammation. In a healthy immune response, it helps fight infections and heal injuries. But in autoimmune conditions, your body produces too much of it, causing chronic inflammation that damages joints, the digestive tract, or skin depending on the disease.
Cimzia binds directly to TNF-alpha and neutralizes it, preventing it from activating the two types of receptors on cell surfaces that would otherwise kick off an inflammatory cascade. It targets both the free-floating form of TNF-alpha circulating in your blood and the version anchored to the surface of immune cells. By shutting down this signaling, Cimzia reduces the swelling, pain, and tissue damage that define conditions like rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, and Crohn’s disease.
How Cimzia Differs From Other TNF Blockers
Several other medications block TNF-alpha, including adalimumab (Humira), infliximab (Remicade), etanercept (Enbrel), and golimumab (Simponi). Those drugs are either full-length antibodies or fusion proteins that all include a region called the Fc fragment. Cimzia doesn’t have one. It uses only the portion of an antibody that binds to TNF-alpha (called the Fab fragment), and nothing else.
That missing Fc region matters for two reasons. First, the Fc fragment is the part of an antibody that gets recognized by receptors in the placenta, which is the mechanism that transfers maternal antibodies to a developing baby. Without it, Cimzia largely stays on the mother’s side of the placental barrier. Second, the Fc region can trigger certain immune responses on its own, so removing it changes how the drug interacts with the immune system.
To compensate for the smaller size of the Fab-only structure (which the kidneys would normally filter out quickly), Cimzia is attached to a branched polyethylene glycol (PEG) molecule, a process called PEGylation. This PEG tail is about 40 kilodaltons in size and serves multiple purposes: it slows kidney clearance enough to give Cimzia a half-life comparable to a full antibody, it improves solubility so the drug can be concentrated enough for a subcutaneous injection, and it reduces how readily immune cells process and present the drug to the rest of the immune system, which may lower the chance of developing anti-drug antibodies.
Why It’s Favored During Pregnancy
The absent Fc region gives Cimzia a practical advantage that no other TNF blocker currently offers. In the CRIB study, researchers measured drug levels in mothers, umbilical cord blood, and infants at birth. Maternal blood levels at delivery were in the normal therapeutic range (median 24.4 micrograms per milliliter). Of 14 infants analyzed, 13 had no detectable Cimzia in their blood at birth, and the one infant with a measurable level had a concentration so low that the infant-to-mother ratio was 0.0009. No infants had detectable levels at four or eight weeks after birth.
These findings indicate that Cimzia does not meaningfully cross the placenta during the third trimester, which is when other TNF blockers can accumulate in fetal circulation through Fc-mediated transport. For people with autoimmune diseases who need continued treatment during pregnancy, this is a significant consideration.
How It’s Taken and How Quickly It Works
Cimzia is given as a subcutaneous injection, typically in the abdomen or thigh. Treatment starts with a loading phase: two 200 mg injections on the first day, then the same dose repeated at week two and week four. After the loading phase, the maintenance schedule is either one injection every two weeks or two injections every four weeks.
Prefilled syringes need to be stored in the refrigerator between 36°F and 46°F (2°C to 8°C). Most people learn to self-inject at home after initial guidance from their healthcare provider.
In clinical trials for axial spondyloarthritis (a group of conditions that includes ankylosing spondylitis), the primary endpoint was measured at week 12, and the drug showed rapid reduction of signs and symptoms over the first 24 weeks. For many patients, noticeable improvement begins within the first few weeks of treatment, though the full benefit can take longer to develop.
Serious Risks to Be Aware Of
Like all TNF blockers, Cimzia carries FDA black box warnings for serious infections and malignancy. Suppressing TNF-alpha dials down part of the immune system, which is exactly what treats autoimmune disease but also leaves you more vulnerable to infections your body would normally handle.
The infections of greatest concern include tuberculosis (including reactivation of a latent infection you may not know you have), invasive fungal infections like histoplasmosis and coccidioidomycosis, and opportunistic bacterial or viral infections. TB can present in unusual forms in people on TNF blockers, spreading beyond the lungs in ways that are harder to diagnose. You’ll be tested for latent TB before starting treatment and monitored periodically afterward.
The malignancy warning notes that lymphoma and other cancers, some fatal, have been reported in children and adolescents treated with TNF blockers as a class. Other serious but less common risks include heart failure, hepatitis B reactivation in carriers, neurological reactions, and significant allergic responses. Most patients who developed serious infections were also taking other immune-suppressing medications like methotrexate or corticosteroids alongside Cimzia, which compounds the risk.
These warnings apply to all TNF blockers, not just Cimzia. The decision to use any of them involves weighing the damage that uncontrolled autoimmune inflammation causes against the risks of immune suppression, a tradeoff that looks different for every patient depending on disease severity and personal health history.